Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer

NCT03750916 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Anlotinib Hydrochloride plus Docetaxel

Sponsor

Qilu Hospital of Shandong University

Collaborators

[object Object]